Louisa M. Bulirsch

ORCID: 0000-0001-5321-9282
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Retinal and Optic Conditions
  • Ocular Surface and Contact Lens
  • Corneal Surgery and Treatments
  • Glaucoma and retinal disorders
  • Bone Tumor Diagnosis and Treatments
  • Retinal Diseases and Treatments
  • Retinal Imaging and Analysis
  • Corneal surgery and disorders
  • Dermatological diseases and infestations
  • Cancer Diagnosis and Treatment
  • Intraocular Surgery and Lenses
  • Hedgehog Signaling Pathway Studies
  • Sarcoidosis and Beryllium Toxicity Research
  • Tumors and Oncological Cases
  • Vascular Malformations Diagnosis and Treatment
  • Management of metastatic bone disease
  • Cerebral Venous Sinus Thrombosis
  • Bartonella species infections research
  • Connective tissue disorders research

University Hospital Bonn
2021-2025

Universitäts-Augenklinik Bonn
2021-2024

Ophthalmology Clinic
2021

University of Bonn
2021

Brolucizumab has recently been approved in Europe as a novel treatment for patients with neovascular age-related macular degeneration (nAMD). We report on early experiences real-world outcomes of switch to brolucizumab therapy previously anti-vascular endothelial growth factor (anti-VEGF)-treated patients.Patients recalcitrant nAMD were switched therapy. Functional and structural parameters 4 weeks after first injection evaluated including best-corrected visual acuity (BCVA (logMAR)), foveal...

10.1136/bjophthalmol-2020-318672 article EN cc-by-nc British Journal of Ophthalmology 2021-04-12

Until now, Schnabel's cavernous optic nerve atrophy (SCONA) has solely been a histopathological diagnosis exhibiting variable degrees of (ON) with characteristic spaces filled acid mucopolysaccharides. We report the first correlation histopathologic findings spectral domain-optical coherence tomography (SD-OCT) imaging in SCONA. examined eye an index patient histopathologically identified SCONA who had undergone multimodal before enucleation for iris ring melanoma. The extent and three other...

10.1038/s41433-025-03603-w article EN cc-by Eye 2025-01-18

ZUSAMMENFASSUNG Bei der Sarkoidose handelt es sich um eine granulomatöse Multisystemerkrankung, die häufig auch am Auge manifestiert, sodass interdisziplinäre Betreuung Patienten unter Einbeziehung des Ophthalmologen notwendig ist. Eine okuläre Beteiligung kann in verschiedenen Augenabschnitten, wie Orbita, Tränendrüse, Bindehaut oder dem Sehnerv zeigen. Allerdings ist Uveitis, vor allem Uveitis anterior, häufigste Augenbeteiligung. adäquate Therapie erforderlich, einen Visusverlust und...

10.1055/a-2317-9942 article DE Arthritis und Rheuma 2024-10-01

10.1007/s00347-024-02147-w article TR other-oa Deleted Journal 2024-11-28
Coming Soon ...